Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic Drug Monitoring of Biologics in Crohn’s Disease
Laurie B. Grossberg, Adam S. Cheifetz, Konstantinos Papamichael
Gastroenterology Clinics of North America (2022) Vol. 51, Iss. 2, pp. 299-317
Closed Access | Times Cited: 10

Showing 10 citing articles:

Overview of therapeutic drug monitoring and clinical practice
Zijun Fang, He Zhang, Jiuchuan Guo, et al.
Talanta (2023) Vol. 266, pp. 124996-124996
Closed Access | Times Cited: 29
Ustekinumab Promotes Radiological Fistula Healing in Perianal Fistulizing Crohn’s Disease: A Retrospective Real-World Analysis
Jiayin Yao, Heng Zhang, Tao Su, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 3, pp. 939-939
Open Access | Times Cited: 12
Validation Study of Novel Point-of-Care Tests for Infliximab, Adalimumab and C-Reactive Protein in Capillary Blood and Calprotectin in Faeces in an Ambulatory Inflammatory Bowel Disease Care Setting
Adriaan Volkers, Mark Löwenberg, Marlou Braad, et al.
Diagnostics (2023) Vol. 13, Iss. 10, pp. 1712-1712
Open Access | Times Cited: 5
The 2023 Impact of Inflammatory Bowel Disease in Canada: Treatment Landscape
Sanjay K. Murthy, Adam V. Weizman, M Ellen Kuenzig, et al.
Journal of the Canadian Association of Gastroenterology (2023) Vol. 6, Iss. Supplement_2, pp. S97-S110
Open Access | Times Cited: 5
90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients
Pasqua Letizia Pesole, Marina Liso, Rossella Donghia, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3955-3955
Open Access | Times Cited: 4
Biologics, small molecule therapies and surgery in small bowel Crohn's disease
Joshua M. Steinberg, Reezwana Chowdhury, Sowmya Sharma, et al.
Current Opinion in Gastroenterology (2024) Vol. 40, Iss. 3, pp. 203-208
Closed Access | Times Cited: 1
Different infliximab induction dosing regimens do not affect remission rates up to 1 year in children with Crohn's disease
Tal Marshanski, Eliana Fanous, Noa Tal, et al.
Journal of Pediatric Gastroenterology and Nutrition (2024) Vol. 79, Iss. 3, pp. 564-572
Closed Access | Times Cited: 1
Surface plasmon resonance assays for the therapeutic drug monitoring of infliximab indicate clinical relevance of anti-infliximab antibody binding properties
Melina K. Grasmeier, Susanne Weber, Matthias Treiber, et al.
Clinical Chemistry and Laboratory Medicine (CCLM) (2023) Vol. 61, Iss. 7, pp. 1255-1265
Open Access | Times Cited: 3
Long-Term Effectiveness and Safety of Proactive Therapeutic Drug Monitoring of Infliximab in Paediatric Inflammatory Bowel Disease: A Real-World Study
Susana Clemente, Óscar Segarra Cantón, Núria Padullés Zamora, et al.
Pharmaceutics (2024) Vol. 16, Iss. 12, pp. 1577-1577
Open Access
Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis?
Janet Pope, Roy Fleischmann
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 2, pp. 161-163
Open Access | Times Cited: 1
Page 1

Scroll to top